2014

Boston Scientific Announces Results For Second Quarter Ended June 30, 2013

NATICK, Mass., July 25, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June 30, 2013.  The company reported GAAP earnings of $0.10 per share.

Second quarter results and recent developments:

  • Exceeded high end of the guidance range with sales of $1.809 billion -- a year-over-year decline of 1 percent on a reported basis and operational growth of 2 percent (constant currency basis, excluding divested businesses). 
  • Delivered adjusted EPS of $0.18, exceeding the company's adjusted EPS guidance range of $0.14 to $0.17.
  • Achieved global year-over-year revenue growth of 21 percent in Neuromodulation on the strength of the Precision Spectra Spinal Cord Stimulator (SCS) System launch, 8 percent in Endoscopy and 5 percent in Peripheral Interventions, all on a constant currency basis.
  • Continued global expansion with combined year-over-year growth of 29 percent in Brazil, Russia, India and China, all on a constant currency basis.
  • Reported positive clinical data related to the Vessix Renal Denervation System, WATCHMAN® Left Atrial Appendage Closure Device, Lotus Aortic Valve System and Vercise Deep Brain Stimulation System - technologies the company believes will help drive growth.
  • Entered into a definitive agreement to acquire the electrophysiology (EP) business of C.R. Bard, Inc., for $275 million in cash. 
  • Generated operating cash flow of $396 million and used $100 million to repurchase approximately 12.5 million shares under the company's existing share repurchase authorizations.

"We are pleased with our improved performance during the quarter," said Mike Mahoney, president and chief executive officer, Boston Scientific.  "As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally."

Worldwide sales for the second quarter:













Three Months Ended









June 30,


% Change


in millions

2013

2012


As Reported Basis

Less: Impact of Foreign Currency

Constant Currency Basis













Interventional Cardiology

$

520


$

549



(5)%

$

(15)


(2)%

(3)%



Peripheral Interventions

199


196



2%

(6)


(3)%

5%



Cardiovascular

719


745



(4)%

(21)


(3)%

(1)%



Cardiac Rhythm Management

475


488



(3)%

(4)


(1)%

(2)%



Electrophysiology

36


37



(3)%

(1)


(1)%

(2)%



Rhythm Management

511


525



(3)%

(5)


(1)%

(2)%



Endoscopy

325


311



5%

(11)


(3)%

8%



Urology/Women's Health

124


126



(1)%

(3)


(2)%

1%



Neuromodulation

111


91



21%

1


0%

21%



MedSurg

560


528



6%

(13)


(3)%

9%












Subtotal Core Businesses

1,790


1,798



0%

(39)


(2)%

2%













Divested Businesses

19


30



(36)%

1


2%

(38)%












Worldwide Net Sales

$

1,809


$

1,828



(1)%

$

(38)


(2)%

1%












Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

 












Sales growth rates that exclude the impact of changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP.  An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.

 


 

On a consolidated GAAP basis, net income for the second quarter of 2013 was $130 million, or earnings of $0.10 per share.  These results included an intangible asset impairment charge, acquisition- and divestiture-related net credits, restructuring-related charges, and amortization expense, of $117 million (after-tax) or $0.08 per share.  Adjusted net income for the second quarter of 2013, excluding these net charges, was $247 million, or $0.18 per share.

On a consolidated GAAP basis, net loss for the second quarter of 2012 was $3.578 billion, or $2.51 per share.  These results included goodwill and other intangible asset impairment charges, acquisition-related net credits, divestiture-, restructuring- and litigation-related charges and amortization expense, of $3.817 billion or $2.68 per share.  Adjusted net income for the second quarter of 2012, excluding these net charges, was $239 million, or $0.17 per share.

Guidance for Third Quarter and Full Year 2013

The company estimates sales for the third quarter of 2013 in a range of $1.700 to $1.760 billion.  The company estimates earnings on a GAAP basis in a range of $0.03 to $0.05 per share.  Adjusted earnings, excluding acquisition- and restructuring-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.14 to $0.16 per share. 

The company estimates sales for the full year 2013 in a range of $7.050 to $7.170 billion.  The company estimates losses on a GAAP basis in a range of ($0.07) to ($0.01) per share.  Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.67 to $0.71 per share. 

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET).  The company will webcast the call to interested parties through its website: www.bostonscientific.com.  Please see the website for details on how to access the webcast.  The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP earnings and adjusted earnings for the third quarter and full year 2013; our financial performance; our business plans; our growth initiatives and expected impact; our positioning for revenue and earnings per share growth; and our product pipeline and its importance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this press release.

Use of Non-GAAP Financial Information

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.

CONTACT:

Denise Kaigler


508-650-8330 (office)


Corporate Affairs & Communications


Boston Scientific Corporation


media@bsci.com




Peter Lucht


508-650-8796 (office)


Global Media Relations


Boston Scientific Corporation


media@bsci.com




Michael Campbell


508-650-8023 (office)


Investor Relations


Boston Scientific Corporation


investor_relations@bsci.com

 

 

 

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

(Unaudited)

 








Three Months Ended


Six Months Ended



June 30,


June 30,

in millions, except per share data

2013


2012



2013


2012









Net sales

$

1,809


$

1,828



$

3,570


$

3,694


Cost of products sold

530


578



1,108


1,209


Gross profit

1,279


1,250



2,462


2,485









Operating expenses:







Selling, general and administrative expenses

661


648



1,292


1,306



Research and development expenses

223


213



427


428



Royalty expense

47


48



87


96



Amortization expense

101


99



204


195



Goodwill impairment charge


3,602



423


3,602



Intangible asset impairment charges

53


129



53


129



Contingent consideration expense (benefit)

(18)


1



(41)


11



Restructuring charges

26


28



36


39



Gain on divestiture

(34)




(40)




Litigation-related charges


69



130


69




1,059


4,837



2,571


5,875


Operating income (loss)

220


(3,587)



(109)


(3,390)









Other income (expense):







Interest expense

(65)


(64)



(130)


(132)



Other, net

(3)


33



(3)


27


Income (loss) before income taxes

152


(3,618)



(242)


(3,495)



Income tax expense (benefit)

22


(40)



(18)


(30)


Net income (loss)

$

130


$

(3,578)



$

(224)


$

(3,465)









Net income (loss) per common share - basic

$

0.10


$

(2.51)



$

(0.17)


$

(2.42)


Net income (loss) per common share - assuming dilution

$

0.10


$

(2.51)



$

(0.17)


$

(2.42)









Weighted-average shares outstanding






Basic

1,343.5


1,423.2



1,347.7


1,434.2


Assuming dilution

1,358.6


1,423.2



1,347.7


1,434.2


 

 

 

 

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

 







As of




June 30,


December 31,

in millions, except share data

2013


2012




(Unaudited)



ASSETS




Current assets:





Cash and cash equivalents

$

530



$

207



Trade accounts receivable, net

1,278



1,217



Inventories

842



884



Deferred income taxes

496



433



Prepaid expenses and other current assets

352



281


Total current assets

3,498



3,022








Property, plant and equipment, net

1,524



1,564


Goodwill

5,553



5,973


Other intangible assets, net

6,026



6,289


Other long-term assets

395



306





$

16,996



$

17,154








LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:





Current debt obligations

$

605



$

4



Accounts payable

251



232



Accrued expenses

1,365



1,284



Other current liabilities

256



252


Total current liabilities

2,477



1,772








Long-term debt

3,647



4,252


Deferred income taxes

1,711



1,713


Other long-term liabilities

2,558



2,547








Commitments and contingencies










Stockholders' equity





Preferred stock, $.01 par value - authorized 50,000,000






shares, none issued and outstanding





Common stock, $.01 par value - authorized 2,000,000,000






shares and issued 1,551,642,655 shares as of June 30,






2013 and 1,542,347,188 shares as of December 31, 2012

16



15



Treasury stock, at cost 212,293,891 shares as of June 30, 2013






and 186,635,532 shares as of December 31, 2012

(1,292)



(1,092)



Additional paid-in capital

16,470



16,429



Accumulated deficit

(8,673)



(8,449)



Accumulated other comprehensive income (loss), net of tax

82



(33)


Total stockholders' equity

6,603



6,870





$

16,996



$

17,154








 

 

 

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

 





Three Months Ended June 30, 2013


in millions, except per share data

Pre-Tax

Tax

Impact (a)

After-Tax

Impact per

diluted share


GAAP net income (loss)

$

152


$

(22)


$

130


$

0.10



Non-GAAP adjustments:







Intangible asset impairment charge

53


(8)


45


0.03




Acquisition-related net charges (credits)

(12)


(2)


(14)


(0.01)




Divestiture-related charges (credits)

(32)


9


(23)


(0.02)




Restructuring and restructuring-related net charges (b)

31


(8)


23


0.02




Amortization expense

101


(15)


86


0.06



Adjusted net income

$

293


$

(46)


$

247


$

0.18



















Three Months Ended June 30, 2012


in millions, except per share data

Pre-Tax

Tax

Impact (a)

After-Tax

Impact per

 diluted share


GAAP net income (loss)

$

(3,618)


$

40


$

(3,578)


$

(2.51)



Non-GAAP adjustments:







Goodwill impairment charge

3,602


(23)


3,579


2.50


*


Intangible asset impairment charge

129


(19)


110


0.08


*


Acquisition-related net charges (credits)

(34)


13


(21)


(0.01)


*


Divestiture-related charges (credits)

1



1


0.00


*


Restructuring and restructuring-related charges (c )

33


(9)


24


0.02


*


Litigation-related net charges

69


(29)


40


0.03


*


Amortization expense

99


(15)


84


0.06


*

Adjusted net income

$

281


$

(42)


$

239


$

0.17










* Assumes dilution of 5.8 million shares for the three months ended June 30, 2012 for all or a portion of these non-GAAP adjustments.


(a) - Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."


(b) In the three months ended June 30, 2013, pre-tax restructuring charges were $26 million and pre-tax restructuring-related charges were $5 million recorded in selling, general and administrative expenses. 


(c) In the three months ended June 30, 2012, pre-tax restructuring charges were $28 million and pre-tax restructuring-related charges were $5 million, of which $2 million was recorded in cost of products sold and $3 million was recorded in selling, general and administrative expenses. 


An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

 

 

 

 

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

 





Six Months Ended June 30, 2013


in millions, except per share data

Pre-Tax

Tax

Impact (a)

After-Tax

Impact per

 diluted share


GAAP net income (loss)

$

(242)


$

18


$

(224)


$

(0.17)



Non-GAAP adjustments:







Goodwill impairment charge

423


(2)


421


0.31


*


Intangible asset impairment charges

53


(8)


45


0.03


*


Acquisition-related net charges (credits)

(35)


(1)


(36)


(0.03)


*


Divestiture-related charges (credits)

(37)


11


(26)


(0.02)


*


Restructuring and restructuring-related net charges (b)

46


(12)


34


0.03


*


Litigation-related charges

130


(48)


82


0.06


*


Amortization expense

204


(29)


175


0.14


*

Adjusted net income

$

542


$

(71)


$

471


$

0.35



















Six Months Ended June 30, 2012


in millions, except per share data

Pre-Tax

Tax

Impact (a)

After-Tax

Impact per

diluted share


GAAP net income (loss)

$

(3,495)


$

30


$

(3,465)


$

(2.42)



Non-GAAP adjustments:







Goodwill impairment charge

3,602


(23)


3,579


2.49


**


Intangible asset impairment charge

129


(19)


110


0.08


**


Acquisition-related net charges (credits)

(21)


11


(10)


(0.01)


**


Divestiture-related charges (credits)

2



2



**


Restructuring and restructuring-related charges (c )

50


(13)


37


0.03


**


Litigation-related net charges

69


(29)


40


0.03


**


Amortization expense

195


(29)


166


0.12


**

Adjusted net income

$

531


$

(72)


$

459


$

0.32










* Assumes dilution of 14.0 million shares for the six months ended June 30, 2013 for all or a portion of these non-GAAP adjustments. 


** Assumes dilution of 7.3 million shares for the six months ended June 30, 2012 for all or a portion of these non-GAAP adjustments.


(a) - Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."


(b) In the six months ended June 30, 2013, pre-tax restructuring charges were $36 million and pre-tax restructuring-related charges were $10 million recorded in selling, general and administrative expenses.


(c) In the six months ended June 30, 2012, pre-tax restructuring charges were $39 million and pre-tax restructuring-related charges were $11 million, of which $6 million was recorded in cost of products sold and $5 million was recorded in selling, general and administrative expenses. 


An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

 

 

 

 

BOSTON SCIENTIFIC CORPORATION

SEGMENT INFORMATION

(Unaudited)

 








Three Months Ended


Six Months Ended

SEGMENT NET SALES*

June 30,


June 30,

in millions

2013

2012**

Change


2013

2012**

Change











        Interventional Cardiology

$

537


$

551


(3)%


$

1,050


$

1,149


(9)%


        Peripheral Interventions

205


196


5%


400


384


4%


Cardiovascular

742


747


(1)%


1,450


1,533


(5)%











        Cardiac Rhythm Management

485


494


(2)%


970


998


(3)%


        Electrophysiology

37


37


(2)%


72


74


(4)%


Rhythm Management

522


531


(2)%


1,042


1,072


(3)%











        Endoscopy

334


309


8%


647


607


6%


        Urology/Women's Health

126


125


1%


245


243


0%


        Neuromodulation

111


92


21%


200


175


14%


MedSurg

571


526


9%


1,092


1,025


6%










Subtotal Core Businesses

1,835


1,804


2%


3,584


3,630


(1)%











Divested Businesses

19


31


(38)%


55


60


(7)%


Foreign Currency

(45)


(7)


N/A


(69)


4


N/A










Worldwide Net Sales

$

1,809


$

1,828


(1)%


$

3,570


$

3,694


(3)%










Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.




















SEGMENT OPERATING INCOME*


Three Months Ended


Six Months Ended





June 30,


June 30,


in millions


2013

2012**


2013

2012**











Segment operating income









Cardiovascular


$

194


$

195



$

364


$

386




Rhythm Management


61


77



124


160




MedSurg


183


150



333


283



Operating income allocated to reportable segments

438


422



821


829




Corporate expenses and currency exchange

(77)


(71)



(146)


(155)




Goodwill and other intangible asset impairment

charges; and acquisition-, divestiture-, restructuring-,

and litigation-related net charges and credits

(40)


(3,839)



(580)


(3,869)




Amortization expense


(101)


(99)



(204)


(195)



Operating income (loss)


$

220


$

(3,587)



$

(109)


$

(3,390)












*We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses.  Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits.  We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuations.  We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; and amortization expense.  Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.


** We have restated prior year information to conform to current year presentation.


An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

 

 

 

 

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE CARDIAC RHYTHM MANAGEMENT (CRM) AND CORONARY STENT SYSTEM SALES

(Unaudited)

 

Three Months Ended June 30


in millions


U.S.


International


Worldwide



Q2 2013

Q2 2012


Q2 2013

Q2 2012


Q2 2013

Q2 2012

Defibrillator systems


$

213


$

220



$

129


$

135



$

342


$

355


Pacemaker systems


69


64



64


69



133


133


Total CRM products


$

282


$

284



$

193


$

204



$

475


$

488









in millions


U.S.


International


Worldwide



Q2 2013

Q2 2012


Q2 2013

Q2 2012


Q2 2013

Q2 2012

Drug-eluting stent systems


$

117


$

140



$

170


$

178



$

287


$

318


Bare-metal stent systems


5


6



12


16



17


22


Total Coronary Stent Systems


$

122


$

146



$

182


$

194



$

304


$

340




Six Months Ended June 30


in millions


U.S.


International


Worldwide



YTD 2013

YTD 2012


YTD 2013

YTD 2012


YTD 2013

YTD 2012

Defibrillator systems


$

434


$

449



$

258


$

274



$

692


$

723


Pacemaker systems


132


127



130


139



262


266


Total CRM products


$

566


$

576



$

388


$

413



$

954


$

989









in millions


U.S.


International


Worldwide



YTD 2013

YTD 2012


YTD 2013

YTD 2012


YTD 2013

YTD 2012

Drug-eluting stent systems


$

234


$

315



$

345


$

366



$

579


$

681


Bare-metal stent systems


10


13



25


33



35


46


Total Coronary Stent Systems


$

244


$

328



$

370


$

399



$

614


$

727


 

 

 

BOSTON SCIENTIFIC CORPORATION

BRIC* NET SALES

(Unaudited)

 

Q2 2013  Percentage change in BRIC Net Sales as compared to Q2 2012

Change

Estimated

As Reported

Constant

Impact of

Currency

Currency

Foreign

Basis

Basis

Currency




29%

29%

0%




*BRIC - Countries comprised of Brazil, Russia, India and China

 

 

 

BOSTON SCIENTIFIC CORPORATION

ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

 

Q3 and Full Year 2013 EPS Guidance



Q3 2013 Estimate


Full Year 2013 Estimate


(Low)

(High)


(Low)

(High)

GAAP results

$

0.03


$

0.05



$

(0.07)


$

(0.01)








Goodwill impairment charge




0.31


0.31


Intangible asset impairment charges




0.03


0.03


Estimated acquisition-related net charges (credits)

0.02


0.02



0.01


0.00


Estimated divestiture-related net credits

(0.01)


(0.01)



(0.02)


(0.02)


Estimated restructuring-related charges

0.04


0.04



0.09


0.08


Litigation-related charges




0.06


0.06


Estimated amortization expense

0.06


0.06



0.26


0.26








Adjusted results

$

0.14


$

0.16



$

0.67


$

0.71








 

An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

Use of Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures that are reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income, adjusted net income per share, and revenue growth rates that exclude certain amounts and/or the impact of changes in foreign currency exchange rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its financial and operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and six months ended June 30, 2013 and 2012, and for the forecasted three month period ending September 30, 2013 and full year ending December 31, 2013, as well as reasons for excluding each of these individual items:

Adjusted Net Income and Adjusted Net Income per Share:

Goodwill and other intangible asset impairment charges - These amounts represent a) a non-cash write-down of our goodwill balance attributable to our global Cardiac Rhythm Management reporting unit in the first quarter of 2013; b) non-cash write-downs of certain intangible asset balances in the second quarter of 2013; c) a non-cash write-down of our goodwill balance attributable to our Europe, Middle East and Africa (EMEA) reporting unit in the second quarter of 2012; and d) a non-cash write-down of certain intangible asset balances in the second quarter of 2012.  We remove the impact of non-cash impairment charges from our operating performance to assist in assessing our cash generated from operations.  We believe this is a critical metric for us in measuring our ability to generate cash and invest in our growth.  Therefore, this charge is excluded from management's assessment of operating performance and is also excluded for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance, particularly in terms of liquidity.

Acquisition-related charges (credits) - These adjustments consist of (a) contingent consideration fair value adjustments, and (b) due diligence, other fees and exit costs. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior acquisitions that are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Divestiture-related expenses (gains) - These amounts represent separation costs or recognized gains associated with the sale of our Neurovascular business in January 2011.  Separation costs and gains on the sale represent those associated with the divestiture and are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Restructuring and restructuring-related costs (credits) - These adjustments represent primarily severance and other direct costs associated with our 2011 Restructuring program. These costs are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these costs for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Litigation-related net charges - These adjustments include certain significant product liability and other litigation-related charges and credits. These amounts are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.  Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Discrete tax items - These items represent adjustments of certain tax positions, which were initially established in prior periods as a result of intangible asset impairment charges; acquisition-, divestiture-, restructuring- or litigation-related charges or credits. These adjustments do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Amortization expense - Amortization expense is a non-cash expense and does not impact our liquidity or compliance with the covenants included in our credit facility agreement. Management removes the impact of amortization from our operating performance to assist in assessing our cash generated from operations.  We believe this is a critical metric for measuring our ability to generate cash and invest in our growth. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.

Revenue Growth Rates Excluding the Impact of Changes in Foreign Currency Exchange Rates

Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing revenue growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Adjusted net income, adjusted net income per share and revenue growth rates that exclude certain amounts and/or the impact of changes in foreign currency exchange rates are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

SOURCE Boston Scientific Corporation



RELATED LINKS
http://www.bostonscientific.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.